Introduction {#s1}
============

Cancer cells rewire their metabolism to sustain uncontrolled cellular proliferation ([@bib28]; [@bib72]). Alterations to cellular metabolism are required to meet the increased energetic and biosynthetic demands of cancer cells ([@bib13]; [@bib72]). Warburg first observed that cancer cells have an increased demand for glucose and increased glycolysis compared to non-cancer cells ([@bib73]). It is now increasingly clear that during transformation and tumorigenesis cancer cells require additional metabolic alterations, which result in dependencies on exogenous metabolites such as the non-essential amino acid glutamine. Although cells can readily synthesize glutamine, several studies have demonstrated that some cancer cells rely on exogenous glutamine and require supplementation for survival ([@bib41]; [@bib15]; [@bib14]; [@bib77]; [@bib1]; [@bib72]). Glutamine is the most abundant amino acid found in blood ([@bib49]) and can be used for a variety of purposes including energy production and generation of biosynthetic intermediates by fueling the TCA cycle ([@bib15]; [@bib77]; [@bib42]; [@bib29]). Glutaminase catalyzes the conversion of glutamine to glutamate and is the rate-limiting enzyme for glutaminolysis ([@bib15]; [@bib16]; [@bib14]; [@bib1]; [@bib11]). Glutamine-derived glutamate is also critical for the generation of the most abundant cellular metabolite, the antioxidant glutathione (GSH), making glutamine metabolism important for maintaining redox homeostasis ([@bib76]; [@bib67]; [@bib79]). Numerous oncogenes drive increased glutamine metabolism, hence targeting glutaminolysis in particular genetic subtypes of cancer has emerged as an attractive therapeutic option ([@bib81]; [@bib23]; [@bib30]; [@bib22]; [@bib78]; [@bib82]; [@bib67]; [@bib55]). Despite extensive studies on the role of glutamine in KRAS-driven tumors ([@bib10]), inhibiting this pathway has led to limited responses in both pre-clinical models ([@bib11]; [@bib2]) and ongoing clinical trials; highlighting the importance of identifying genetic subtypes of cancer that may have a greater dependency on glutamine.

During tumor initiation and progression, increased metabolic output as well as changing environmental conditions result in high oxidative stress in the form of reactive oxygen species (ROS)([@bib5]). The role of ROS in the development and progression of cancer has been the subject of considerable study and debate ([@bib7]; [@bib8]). Emerging evidence supports the idea that cancers increase antioxidant capacity as a stress response mechanism, suggesting that high ROS levels may constitute a barrier to tumor progression ([@bib59]; [@bib44]; [@bib54]). To maintain oxidative homeostasis, cancer cells increase their antioxidant capacity ([@bib71]). Under normal physiologic conditions, the KEAP1/NRF2 signaling axis is responsible for coordinating the cell's antioxidant defenses in response to ROS. KEAP1 binds to NRF2 and enables the CUL3-mediated ubiquitination and proteasomal degradation of NRF2 ([@bib37]). When ROS increase, KEAP1 oxidation leads to a conformational change enabling the dissociation and stabilization of NRF2, which translocates to the nucleus to induce the transcription of a battery of antioxidant genes ([@bib32]; [@bib33]), including enzymes regulating the synthesis of the major cellular antioxidant GSH, and enzymes involved in the reduction of oxidized GSH and thioredoxin (TXN)([@bib25]). The activation of the antioxidant response requires the flux of glucose and glutamine-derived carbons and cofactors (e.g. NAD/NADH, NADP/NADPH) to be diverted to antioxidant production ([@bib50]; [@bib65]). Increased flux of nutrients to antioxidant production may limit nutrient availability for other biosynthetic pathways.

However, in the context of chronic ROS exposure, post-transcriptional or post-translational signaling can stabilize NRF2 ([@bib24]), or epigenetic ([@bib51]; [@bib27]; [@bib19]) and genetic events can lead to NRF2 stabilization ([@bib62]; [@bib35]; [@bib39]; [@bib34]; [@bib58]), resulting in the chronic activation of NRF2 and its downstream antioxidant program ([@bib53]; [@bib62]; [@bib63]). Interestingly, *KEAP1* is the third most frequently mutated gene in lung adenocarcinoma (LUAD) and often co-occurs with oncogenic mutations in *KRAS* ([@bib6]). Activation of the NRF2-driven antioxidant axis may create a unique set of metabolic requirements necessary to sustain this increased antioxidant capacity ([@bib50]; [@bib17]; [@bib40]), creating potential for novel therapeutic vulnerabilities in aggressive lung cancers.

Here we demonstrate that *KEAP1* loss of function (LOF) mutations drive increased dependency on glutamine in both mouse and human KRAS-driven LUAD cell lines. We show that *KEAP1* mutant cells have decreased intracellular glutamate pools through increased glutamate consumption for GSH synthesis and by exporting glutamate through the antiporter xCT in exchange for cystine. The low intracellular pools of glutamate lead to increased sensitivity to glutamine deprivation and glutaminase inhibition in an xCT dependent fashion. Using a small molecule activator of NRF2, we provide evidence that acute NRF2 activation is sufficient to rewire cellular metabolism, similar to that of *KEAP1* mutant cells, and leads to glutamine dependency due to a basal deficiency in anaplerosis. Finally, we show that this is a phenomenon that occurs across multiple types of cancers with *KEAP1* mutations, and demonstrate the importance of sub-stratifying patients based on genotype to maximize therapeutic efficacy of glutaminase inhibition in clinical trials and pre-clinical models where responses have been previously limited ([@bib11]; [@bib2]).

Results {#s2}
=======

KEAP1 mutations cause increased dependency on exogenous glutamine {#s2-1}
-----------------------------------------------------------------

To study the role of *Keap1* mutations in rewiring lung cancer metabolism, we generated isogenic Kras-driven, *Trp53* null (Kras^G12D/+^; p53^-/-^; hereafter KP) cells with wild-type (KP) or LOF mutations in *Keap1* (KPK) using CRISPR/Cas9-editing. We observed that KPK cells had increased production of GSH compared to KP cells ([Figure 1A](#fig1){ref-type="fig"}), as a result of increased levels of glutamate-cysteine ligase catalytic subunit, *Gclc*, which along with glutamate-cysteine ligase modifier subunit, *Gclm* synthesize GSH ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}). As expected, elevated levels of GSH in KPK cells corresponded with decreased levels of cellular ROS ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Both KP and KPK cells had similar growth rates under basal conditions ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), however when challenged with oxidative stress, KPK cells were more resistant compared to KP cells ([Figure 1B and C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}).

![*Keap1* mutations cause increased dependency on exogenous glutamine.\
(**a**) Measurement of whole cell glutathione levels in wild type (KP) and *Keap1* mutant (KPK) in isogenic clones derived from mouse lung tumors (*n* = 3, triplicate wells). (**b**) Relative viability assayed with cell-titer glo (relative luminescent units) in KP and KPK cells in RPMI after treatment with H~2~O~2~ for 12 hr. All data points are relative to vehicle treated controls (*n* = 8/data point from replicate wells) (**c**) Relative viability assayed with cell-titer glo (relative luminescent units) in KP and KPK cells in RPMI after treatment with galactose oxidase for 72 hr. All data points are relative to vehicle treated controls (*n* = 4/data point from replicate wells). **d**) Measurement of whole cell glutathione levels in KP and KPK cells after 24 hr of CB-839 treatment where indicated (*n* = 3, triplicate wells). (**e**) Intracellular glutamate levels per cell (*n* = 6, two independent experiments with triplicate wells). (**f**) Glutamate secretion in KP and KPK cells (*n* = 6, two independent experiments with triplicate wells). All error bars depict s.e.m. \*\*p\<0.01, \*\*\*\*p\<0.0001.](elife-28083-fig1){#fig1}

GSH is a tri-peptide composed of glutamate, cysteine, and glycine. Therefore, we conjectured that high levels of GSH in KPK cells might result in increased demand for glutamate and consequently KPK cells would be more dependent on glutamine-derived glutamate compared to KP cells. Indeed, decreasing glutamine concentrations in the media substantially decreased proliferation of KPK cells with minimal effects on KP cells ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). Glutaminase catalyzes the conversion of glutamine to glutamate and is the rate-limiting enzyme for glutaminolysis ([@bib15]; [@bib14]; [@bib1]; [@bib11]). Here we use a small molecule inhibitor of glutaminase, CB-839, which is currently in clinical phase I trials for multiple cancer types, including LUAD. CB-839 blocks glutamine catabolism and decreases the availability of glutamate in the cell for GSH antioxidant production and the generation of α-ketoglutarate (αKG) as a carbon source for the TCA cycle and other biosynthetic intermediates ([@bib1]). Consistent with glutamine deprivation, KPK cells had increased sensitivity to CB-839, ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). In line with CB-839 decreasing glutamate availability, cellular glutathione levels were reduced after CB-839 treatment ([Figure 1D](#fig1){ref-type="fig"}). Increased sensitivity to both glutamine deprivation as well as glutaminase inhibition suggests that *Keap1* mutant lung cancers depend on glutamine-derived glutamate to support GSH synthesis.

xCT/Slc7a11-dependent glutamate secretion in *Keap1* mutant cells causes glutamine dependency {#s2-2}
---------------------------------------------------------------------------------------------

To elucidate the mechanism of glutamine dependency in *Keap1* mutant cells resulting from increased cellular glutamate demand, we measured both intra- and extra-cellular glutamate levels. Surprisingly, KPK cells had lower intracellular but higher extracellular levels of glutamate when compared to KP cells ([Figure 1E and F](#fig1){ref-type="fig"}). Glutamate is required for the synthesis of GSH, but is also necessary for the import of cystine via the x~c~^-^ antiporter system (xCT), which exchanges glutamate for cystine across the plasma membrane in order to support intracellular cysteine pools for antioxidant production ([Figure 2A](#fig2){ref-type="fig"}) ([@bib46]). Previously, expression of xCT has been linked with glutamine sensitivity and to antagonize glutamine anaplerosis ([@bib70]; [@bib64]). xCT is a heterodimer of Slc7a11, a *bona-fide* Nrf2 target gene, and Slc3a2 ([@bib46]). Consistent with prior findings ([@bib31]; [@bib46]; [@bib26]), gene expression analysis revealed dramatically higher levels of Slc7a11 in KPK cells compared to KP controls ([Figure 2B](#fig2){ref-type="fig"}). We hypothesized that the Nrf2-driven increase in expression of *Slc7a11* and *Gclc*, and higher levels of GSH in KPK cells may result in export of glutamate in exchange for import of cystine ([Figure 2A](#fig2){ref-type="fig"}). To determine if xCT/Slc7a11 is responsible for the KPK cell dependency on exogenous glutamine, we treated cells with a small molecule inhibitor of xCT, Erastin ([@bib18]). Indeed, Erastin treatment was sufficient to rescue the growth suppressive effects of both glutamine deprivation and CB-839 treatment in KPK cells with little effect on KP cells ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Furthermore, through the examination of a panel of human LUAD cell lines, we demonstrate that *KEAP1* mutants are robustly sensitive to glutaminase inhibition ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Importantly, pre-treatment with Erastin overcomes sensitivity to glutaminase inhibition in *KEAP1* mutant lines ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). xCT/Slc7a11 functions based on the intra- and extra- cellular gradients of cystine and glutamate in a concentration dependent manner ([@bib4] [@bib74]). Therefore, we asked whether we could rescue glutamine dependency of KPK cells by forcing the export of cystine and the import of glutamate by modulating the concentration of these two amino acids in the culture media. By either raising the levels of glutamate or lowering the levels of cystine we were able to rescue proliferation in KPK cells after CB-839 treatment ([Figure 2D and E](#fig2){ref-type="fig"}). To further validate that CB-839 sensitivity in KPK cells is dependent on xCT/Slc7a11, we tested multiple doxycycline inducible mirE based shRNAs targeting Slc7a11 ([Figure 2---figure supplement 2A and B](#fig2s2){ref-type="fig"}). In line with expectations, knockdown of Slc7a11 by two independent shRNAs rescued KPK cells from both CB-839 treatment as well as glutamine deprivation while shCTRL had no effect ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). In addition, modulating the levels of glutamate or cystine in the media did not provide additional benefits to depletion of Slc7a11 in regards to sensitivity to CB-839 or glutamine deprivation ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Taken together, these results indicate that increased expression of xCT/Slc7a11 through Nrf2 hyperactivation in *Keap1* mutant cells is necessary for the increased glutamine dependency and sensitivity to glutaminase inhibitors.

![xCT/Slc7a11-dependent glutamate secretion in *Keap1* mutant cells causes glutamine dependency.\
(**a**) Schematic depicting glutaminolysis and subsequent glutamate export by the xCT/Slc7a11 antiporter. Treatment with the small molecule CB-839 inhibits Gls1, blocking the conversion of glutamine to glutamate while the small molecule Erastin inhibits Slc7a11 preventing glutamate export. (**b**) Quantitative real-time PCR of mRNA expression of *Slc7a11* in KP and KPK cells (*n* = 3, technical replicates). Data presented as relative to *Slc7a11* expression in KP cells. (**c**) Proliferation of KP and KPK cells after overnight pretreatment with 500 nM Erastin followed by 250 nM CB-839 treatment for 5 days (*n* = 3, triplicate wells). Data presented as relative to vehicle only treated condition for each cell line. (**d**) Proliferation of KP and KPK cells after addition of 6 mM glutamate followed by 250 nM CB-839 treatment for 5 days (*n* = 3, triplicate wells). Data presented as relative to vehicle only treated condition for each cell line. (**e**) Proliferation of KP and KPK cells in media containing low cystine (20 μM, 10X reduction from RPMI which contains 208 μM cystine) followed by 250 nM CB-839 treatment for 5 days (*n* = 3, triplicate wells). Data presented as relative to vehicle only treated condition for each cell line. (**f**) Proliferation of KP and KPK expressing either a doxycycline inducible control shRNA (shCTRL) or an shRNA targeted against Slc7a11 (shSlc7a11). Cells were cultured in RPMI with or without doxycycline that was supplemented with 6 mM glutamate or RPMI containing low cystine (20 μM, 10X reduction from RPMI which contains 208 μM cystine) followed by 250 nM CB-839 treatment for 5 days (*n* = 3, triplicate wells). (**g**) Subcutaneous tumor volumes of KPK tumors expressing a doxycycline inducible control shRNA (sh*Ctrl*). Animals were treated with vehicle (black) or CB-839 (blue) and received normal (solid line) or doxycycline (dashed line) feed starting from day 13 (arrow indicating treatment start, *n* = 6 tumors) (**h**) Subcutaneous tumor volumes of KPK tumors expressing a doxycycline inducible shRNA targeted against Slc7a11 (shSlc7a11). Animals were treated with vehicle (black) or CB839 (blue) and received normal (solid line) or doxycycline (dashed line) feed starting from day 13 (arrow indicating treatment start, *n* = 6 tumors). All error bars depict s.e.m. \*\*\*\*p\<0.0001.](elife-28083-fig2){#fig2}

*Keap1* mutations that activate Nrf2 result in elevated GSH production thereby leaving *Keap1* mutant cells highly dependent on glutaminolysis and susceptible to glutaminase inhibition in vitro. However, the extracellular environment can greatly affect cellular metabolism, and culturing cells in vitro versus in vivo can significantly alter their metabolic requirements ([@bib11]). To assess the importance of xCT/Slc7a11 in driving sensitivity to glutaminase inhibition in KPK cells in vivo, we implanted KP and KPK cells that expressed inducible shRNA constructs against Slc7a11 or CTRL subcutaneously in mice. After tumors were established, mice were randomized to groups to receive oral CB-839 or vehicle twice daily and to receive a doxycycline or control diet to induce shRNA expression. CB-839 treatment suppressed tumor growth only in KPK cells, but had no effect on KP tumors ([Figure 2G and H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2D and E](#fig2s2){ref-type="fig"}). Knockdown of Slc7a11 completely abrogated the effect of CB-839 on KPK tumors ([Figure 2H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}). These data strongly support the notion that *Keap1* mutations result in a metabolic liability to glutaminase inhibition in vivo driven by increased expression of xCT/Slc7a11 in KPK cells.

*Keap1* mutants have defects in TCA cycle anaplerosis {#s2-3}
-----------------------------------------------------

*Keap1* mutant cells are dependent on glutamine due to basally decreased intracellular pools of glutamate, partially because of increased secretion via xCT and increased production of GSH. Glutamate can fuel both GSH synthesis, or via transamination be converted to α-KG, a carbon source for the TCA cycle ([Figure 3A](#fig3){ref-type="fig"}). To assess whether limited glutamate availability for GSH synthesis leads to proliferation defects, we pretreated KPK cells with the antioxidants trolox (Vitamin E analog) or N-acetyl cysteine (NAC). However, supplementation with these antioxidants did not rescue proliferation after glutamine deprivation or glutaminase inhibition in KPK cells ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}). We hypothesized that high antioxidant production in KPK cells driven by Nrf2 activation increases cellular demand for glutamate. Glutamate is required in order to synthesize glutathione while limiting availability for other cellular processes such as fueling the TCA cycle. Consistent with this hypothesis, pretreatment with: (1) dimethyl 2-oxoglutarate (DMG), a cell permeable α-KG analogue, or (2) pyruvate, a glucose-derived TCA cycle carbon source, rescued sensitivity to CB-839 and glutamine deprivation in KPK cells ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These results suggest that sensitivity to glutaminase inhibition is due to decreased glutamate availability for anaplerosis or other biosynthetic reactions, not synthesis of the antioxidant GSH. In line with this, reducing GSH levels in KPK cells with L-Buthionine sulfoximine (BSO) did not alter sensitivity to CB-839 ([Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}).

![*Keap1* mutants have defects in glutamine anaplerosis.\
(**a**) Schematic depicting glutaminolysis and subsequent glutamate export by the xCT/Slc7a11 antiporter. Treatment with the small molecule CB-839 inhibits Gls1, blocking the conversion of glutamine to glutamate. Treatment with the antioxidants N-acetylcysteine (NAC) or trolox scavenge cellular reactive oxygen species (ROS) while treatment with either pyruvate or dimethyl 2-oxoglutarate (DMG) provide carbons to the TCA cycle (**b**) Proliferation of KP and KPK cells after overnight pretreatment with either 500 nM NAC, 500 nM Trolox, 2 mM pyruvate or 2 mM DMG followed by 250 nM CB-839 treatment for 5 days (*n* = 3, triplicate wells). Data presented as relative to vehicle only treated condition for each cell line. (**c**) Relative abundance of TCA cycle metabolites in KP and KPK cells supplemented with 2 mM pyruvate or DMG where indicated (*n* = 3, triplicate wells). Data is normalized by cell counts for each cell line in each condition. (**d**) Schematic depicting the TCA cycle. Filled blue circles represent ^13^C atoms derived from \[U-^13^C\]-L glutamine. (**e**) Mass isotopomer analysis of TCA cycle metabolites in KP and KPK cells cultured for 8 hr with \[U-^13^C\]-L glutamine (*n* = 3, triplicate wells). (**f**) Relative mitochondrial respiration measured by oxygen consumption rate (OCR, pmol O~2~/min) in KP and KPK cells treated either with vehicle or 250 nM CB-839 for 4 hr (*n* = 5, replicate wells). Data is presented as relative to vehicle treated KP cells. (**g**) Relative mitochondrial respiration measured by oxygen consumption rate (OCR, pmol O~2~/min) in KP and KPK cells pretreated either 2 mM pyruvate or 2 mM DMG followed by treatment with vehicle or 250 nM CB-839 for 4 hr (*n* = 3, triplicate wells). Data is presented as relative to vehicle treated KP cells. (**h**) Schematic depicting the entry of glucose derived carbon into the TCA cycle via pyruvate carboxylase activity. Filled circles represent ^13^C atoms derived from \[3^13^C\]-D glucose (blue) or \[1^13^C\]-pyruvate (green). Carbon flux through pyruvate carboxylase results in M + 1 labeled citrate while flux through pyruvate dehydrogenase results in unlabeled citrate. (**i**) Mass isotopermer analysis of citrate in KP and KPK cells cultured for 8 hr with \[3^13^C\]-D glucose and 250 nM CB-839 where indicated (*n* = 3, triplicate wells). Data is normalized with respect to M + 1 pyruvate to account for differences in basal rates of glycolysis. (**j**) Mass isotopermer analysis of citrate in KP and KPK cells pretreated with \[1^13^C\]-pyruvate overnight and then treated 250 nM CB-839 for 8 hr where indicated (*n* = 3, triplicate wells). Data is normalized with respect to M + 1 pyruvate to account for differences in basal rates of glycolysis. All error bars depict s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001.](elife-28083-fig3){#fig3}

Our data suggests that hyperactivation of Nrf2 by *Keap1* mutation genetically reprograms cells to produce high levels of antioxidants at the expense of contributing carbon to replenish the TCA cycle. Consistent with this data, KPK cells have reduced total levels of TCA cycle intermediates ([Figure 3C](#fig3){ref-type="fig"}) and supplementation with either 2 mM pyruvate or DMG increased total levels of TCA cycle intermediates in KPK cells equivalent to or in excess to those in KP cells ([Figure 3C](#fig3){ref-type="fig"}). To determine the fate of glutamine, we used a stable-isotope labeled glutamine tracer (U-C^13^-L-glutamine) ([Figure 3D](#fig3){ref-type="fig"}). We observed that KPK cells incorporate less carbon from glutamine into the TCA cycle as compared to KP cells ([Figure 3E](#fig3){ref-type="fig"}). Taken together, these data strongly suggest that KPK cells have a basal deficiency in glutamine metabolism that contributes to their increased sensitivity to loss of glutamine-derived glutamate for anaplerosis. A functional output of the TCA cycle is oxidative phosphorylation in the mitochondria, as the TCA cycle generates NADH and FADH~2~ that will be used by the mitochondrial electron transport system to produce ATP. Measuring mitochondrial respiration revealed that KPK cells have reduced oxygen consumption rates (OCR) compared to KP cells indicating that *Keap1* mutants have lower mitochondrial respiration basally ([Figure 3F](#fig3){ref-type="fig"}). The overall decrease in respiration in KPK compared to KP cells is in line with decreased TCA cycle output ([Figure 3C](#fig3){ref-type="fig"}). However, supplementation with pyruvate or DMG did not significantly increase basal OCR in KPK cells ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). This is likely a result of KPK cells having reduced reserve respiratory capacity as compared to KP cells ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}) in normal media conditions. As expected, CB-839 treatment reduced respiration in both KP and KPK cells, however, the drop in OCR after CB-839 administration was dramatically more pronounced in KPK cells (−50.8%) compared to KP cells (−21.6%), despite baseline levels being lower in KPK cells ([Figure 3F and G](#fig3){ref-type="fig"}). The drop in OCR in response to CB-839 was rescued by co-treatment with DMG or pyruvate ([Figure 3G](#fig3){ref-type="fig"}). The ability of both DMG and pyruvate to rescue overall levels of TCA cycle metabolites as well as cellular proliferation and mitochondrial respiration in response to CB-839 treatment in KPK cells suggests that the basal defects in TCA cycle metabolism in KPK cells causes a metabolic bottleneck due to limited glutamate availability which is further exacerbated by glutaminase inhibition via CB-839. As an αKG analogue, DMG can directly fuel the TCA cycle and bypass glutaminase inhibition. However, the ability of pyruvate to rescue TCA cycle defects in KPK cells is less direct. One explanation is that pyruvate offers an alternative anaplerotic substrate via increased flux through pyruvate carboxylase, which catalyzes the conversion of pyruvate to oxaloacetate. To determine if treatment with CB-839 enhanced carbon flux through pyruvate carboxylase (PC), we performed stable isotope tracing using \[3 C^13^\]-D-glucose to look at PC flux in basal conditions as well as with \[1 C^13^\]-pyruvate to look at flux in rescue conditions ([Figure 3H](#fig3){ref-type="fig"}). In line with this hypothesis, we observed increased flux through pyruvate carboxylase in response to CB-839 in normal media conditions as well as when cells are supplemented with pyruvate ([Figure 3I and J](#fig3){ref-type="fig"}). This is in agreement with previous results indicating that KP tumors have increased PC flux ([@bib11]).

Taken together these data show that *Keap1* mutations result in basal defects in central carbon metabolism, with KPK cells having overall decreased levels of TCA cycle intermediates and reduced contribution of carbon from glutamine to these metabolites. This metabolic imbalance in KPK cells can be therapeutically exploited by the use of glutaminase inhibitors to further limit glutamate availability.

Nrf2 activation is sufficient to sensitize cells to glutaminase inhibition and *Keap1* mutations predict sensitivity across multiple cancer types {#s2-4}
-------------------------------------------------------------------------------------------------------------------------------------------------

Having established that *Keap1* mutations increase sensitivity to glutaminase inhibition, we sought to determine if activation of Nrf2 in wild type cells would be sufficient to sensitize cells to CB-839. Using a small-molecule activator that disrupts the binding of Keap1 to Nrf2, KI696 ([@bib12]), we first validated that treatment with KI696 could increase Nrf2 protein levels as well as increase expression of downstream target genes in KP cells ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} 1A). Pretreatment with KI696 and subsequent Nrf2 activation was sufficient to induce strong growth suppression in response to CB-839 treatment in KP cells ([Figure 4B](#fig4){ref-type="fig"}), similar to what we observed in KPK cells ([Figure 2C](#fig2){ref-type="fig"}). Additionally, effects of CB-839 were rescued both by pretreatment of anaplerotic precursors, pyruvate and DMG, and by modulating extracellular glutamate and cystine concentrations, but not by the antioxidants NAC and trolox ([Figure 4B](#fig4){ref-type="fig"}).

![Nrf2 activation is sufficient to sensitize cells to glutaminase inhibition.\
(**a**) Quantitative real-time PCR of mRNA expression of *Nqo1* in KP, KPK, and KPN (Nrf2 null) cells after pretreatment with 1 μM KI696 for 36 hr (*n* = 3, technical replicates). Data presented as relative to *Nqo1* expression in untreated KP cells. (**b**) Proliferation of KP cells after pretreatment with the small molecule activator of Nrf2, 1 μM KI696, followed by treatment with either 500 nM NAC, 500 nM trolox, 2 mM pyruvate, 2 mM DMG, supplementation with 6 mM glutamate, or media containing low cystine (20 μM, 10X reduction from RPMI which contains 208 μM cystine) followed by 250 nM CB-839 treatment for 5 days (*n* = 5, replicate wells). Data is presented as relative to vehicle treated. (**c) Left:** Schematic depicting CRISPR synergistic activation mediated (SAM) system. A modified sgRNA recruits catalytically dead Cas9 that is fused to VP64 to promoter regions up stream of the transcription start site of target genes and recruits additional transcriptional activators to induced endogenous transcription of target genes. **Right:** Quantitative real-time PCR of mRNA expression of *Gclc*, *Gclm*, and *Slc7a11* in KP SAM CRISPRa cell lines with sgRNAs targeting each gene of interest (*n* = 3, technical replicates). Data presented as relative to expression of each gene in sgCtrl cells. (**d**) Proliferation of KP SAM CRISPRa cells expressing sgRNAs against Gclc, Gclm, and Slc7a11. Cells were seeded in media lacking glutamate and after 24 hr were treated with 100 nM of CB-839 for 5 days (*n* = 3, replicate wells). Data is presented as relative to vehicle treated control for each cell line. (**e**) Western blot depicting Nrf2 expression in *KEAP1* wild type human lung adenocarcinoma line (H2009) after treatment with KI696. Cells were treated with 1 μM KI696 for 36 hr and then nuclear (**N**) and cytoplasmic (**C**) fractions were collected. First panel depicts an Nrf2 blot, second panel depicts an Hsp90 loading control for cytoplasmic fraction, and third panel depicts an H3 loading control for nuclear fraction. **f**) Proliferation of *KEAP1* wild type human lung cancer cell line H2009 after pretreatment with the small molecule activator of NRF2, 1 μM KI696, followed by treatment with either 500 nM NAC, 500 nM trolox, 2 mM pyruvate, 2 mM DMG, supplementation with 6 mM glutamate, or media with reduced cystine (20 uM) followed by 250 nM CB-839 treatment for 5 days (*n* = 5, replicate wells). Data is presented as relative to vehicle treated. (**g**) Relative abundance of TCA cycle metabolites in KP, KPK, and KP cells treated with 1 μM KI696 (*n* = 3, triplicate wells). Data is normalized by cell counts for each cell line. (**h**) Relative mitochondrial respiration measured by oxygen consumption rate (OCR, pmol O~2~/min) in KP cells treated with either vehicle or 1 μM KI696 followed by treatment with vehicle or 250 nM CB-839 for 4 hr (*n* = 3, triplicate wells). Data is presented as relative to vehicle treated KP cells. All error bars depict s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-28083-fig4){#fig4}

Additionally, we took a genetic approach to elevate GSH levels in KP cells in order to reproduce the *Keap1* mutant phenotype in wild type cells and sensitize them to CB-839. Using the CRISPR synergistic activation mediate (CRISPRa SAM) system ([@bib38]) ([Figure 4C](#fig4){ref-type="fig"}), which takes advantage of the DNA targeting capabilities of a catalytically dead Cas9 protein fused to VP64 and a modified sgRNA that recruits and targets transcriptional activators to promoter regions upstream of transcriptional start sites of genes of interest to enhance endogenous transcription. Using sgRNAs that target the promoters of *Gclc, Gclm,* and *Slc7a11*, we were able to increase mRNA expression in cells that expressed single sgRNAs to each gene as well as in cells that expressed two sgRNAs to increase expression of *Slc7a11* and *Gclc* or *Gclm* in combination ([Figure 4C](#fig4){ref-type="fig"}). Increased expression of these Nrf2 target genes resulted in significant increases in total GSH in all cell lines ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). However, we only observed increased sensitivity to CB-839 in KP cells that had increased expression of *Slc7a11* in combination with either *Gclc* or *Gclm* ([Figure 4D](#fig4){ref-type="fig"}).

Similar to mouse KP cells, human *KEAP1* wild type lung cancer cells, H2009, responded to KI696 with nuclear accumulation of NRF2 and subsequent up regulation of target gene expression and total GSH levels ([Figure 4E](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2A--C](#fig4s2){ref-type="fig"}). In line with KP cells, human H2009 cells responded strongly to co-treatment with CB-839 and KI696 and this synergistic effect was rescued by pretreatment of anaplerotic precursors, modulating extracellular glutamate and cystine concentrations but not by antioxidants ([Figure 4F](#fig4){ref-type="fig"}). We next asked if KI696 treatment would replicate the metabolic phenotypes observed in KPK cells. KP cells treated with KI696 had reduced total levels of TCA cycle intermediates ([Figure 4G](#fig4){ref-type="fig"}), equivalent to that observed in KPK cells ([Figure 4G](#fig4){ref-type="fig"} and [Figure 3C](#fig3){ref-type="fig"}). Additionally, overall mitochondrial respiration was reduced upon treatment of wild type KP cells with KI696, and further reduced by the addition of CB-839 ([Figure 4H](#fig4){ref-type="fig"}). These data demonstrate that Nrf2 activation is sufficient to rewire cellular metabolism, resulting in increased glutamine dependency and sensitivity to CB-839 treatment in both mouse and human LUAD lines.

In addition to LUAD, *KEAP1/NRF2* mutations are found in other cancers ([@bib62]; [@bib35]; [@bib39]; [@bib51]; [@bib6]; [@bib27]; [@bib34]; [@bib58]; [@bib24]; [@bib19]). To assess whether NRF2 promotes glutamine dependency in other *KEAP1* mutant cancers, we tested CB-839 on a panel of human cancer cell lines with WT or mutant *KEAP1*, including melanoma, bone, colon, renal, squamous and urinary tract cancers. For each cancer type, mutations in *KEAP1* predicted sensitivity to CB-839 ([Figure 5A](#fig5){ref-type="fig"}). Importantly, co-treatment with KI696 was able to sensitize *KEAP1* wild type cancer cells that were relatively insensitive to CB-839 ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Taken together, our data suggests that glutaminase is an attractive target in both lung adenocarcinoma and in other cancers in which the KEAP1/NRF2 axis is mutated and the glutaminase inhibitor CB-839 could be an effective therapeutic agent in patients with these genetic subtypes of cancer. Additionally, glutaminase inhibition could be more broadly applicable in a variety of cancer types when combined with a small molecule activator of NRF2, which renders *KEAP*1 wild type cells highly sensitive to glutaminase inhibition.

![*KEAP1* mutations predict sensitivity to glutaminase inhibitors across multiple cancer subtypes.\
(**a**) Proliferation of a panel of human cancer cell lines of various tissues of origin treated with vehicle or 250 nM CB-839 for 4 days. One wild type and one *KEAP1* mutant cell line assessed for each tissue (*n* = 3, triplicate wells). Data is presented as relative to vehicle treated. (**b**) Proliferation of cell lines shown in (**a**) along with pretreatment of 1 μM KI696 in *KEAP1* wild type cells followed by 250 nM CB-839 treatment for 4 days. Each data point represents an independent cell line (*n* = 3, triplicate wells). Data is presented as relative to vehicle treated. (**c**) Schematic depicting how constitutive NRF2 activation via *KEAP1* mutations or use of small molecule activator, KI696, results in increased glutathione production and high xCT/SLC7A11 expression. Increased GSH production increases cellular demand for glutamate, making *KEAP1* mutant cells glutamine dependent and susceptible to glutaminase inhibition. (**d**) Schematic depicting the balance between cellular production of antioxidants and demand for cysteine versus using glutamate to fuel anaplerosis (left). Activation of Nrf2 results in an imbalance between production of antioxidants and use of glutamate for anaplerosis that can be exploited by CB-839 treatment to further limit glutamate availability (right). All error bars depict s.e.m. \*\*\*\*p\<0.0001.](elife-28083-fig5){#fig5}

Discussion {#s3}
==========

Tumorigenesis requires cancer cells to increase their metabolic output to support tumor growth. Higher metabolic activity increases oxidative stress in the form of ROS, which can lead to oxidative damage of macromolecules. Under physiologic conditions of increased ROS, the NRF2 stress response promotes an antioxidant network that will scavenge and clear ROS. After ROS clearance NRF2 will once again be degraded through its interaction with KEAP1 and CUL3-mediated ubiquitination. However, in the context of chronic ROS exposure, post-transcriptional or post-translational signaling which stabilize NRF2 ([@bib24]), or epigenetic ([@bib51]; [@bib27]; [@bib19]) and genetic events that lead to NRF2 stabilization ([@bib62]; [@bib35]; [@bib39]; [@bib34]; [@bib58]), NRF2 and its downstream antioxidant program will be chronically activated ([Figure 5C](#fig5){ref-type="fig"}). NRF2 activation subsequently leads to changes in cellular metabolism to support increased synthesis of antioxidants ([@bib50]; [@bib17]), which have recently been shown to promote tumorigenesis ([@bib57]). In this study, we show that NRF2 dependent metabolic alterations result in a unique set of metabolic requirements in *KEAP1* mutant cells that can consequently be theraputically exploited.

We show that constitutive (*KEAP1* mutation) or pharmacological activation of NRF2 leads to alterations in glutamine metabolism and defective glutamate-dependent fueling of central carbon metabolism ([Figure 5D](#fig5){ref-type="fig"}). Glutamine is a critical nutrient for proliferating cells as it contributes to supporting cellular bioenergetics by fueling ATP production as well as supplying the cell with necessary intermediates for biosynthesis ([@bib16]). Both the carbon and nitrogen derived from glutamine are used for the synthesis of nucleotides, amino acids, and other macromolecules. Nitrogen from glutamine contributes to de novo nucleotide synthesis making an adequate supply of glutamine to support purine and pyrimidine synthesis necessary to maintain rapid rates of proliferation ([@bib69]). Additionally, carbon and nitrogen from both glutamine and glutamate support amino acid synthesis via the activity of a variety of transaminases and aminotransferases ([@bib14]). Depleted intracellular glutamate levels in *KEAP1* mutant cells likely alters the activity of various transaminases due to limited substrate availability and may also result in the dependency on other exogenously supplied metabolites ([@bib13]). The decreased availability of intracellular glutamate we observe in *KEAP1* mutant cells results in dependency on exogenous glutamine ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), which can be therapeutically exploited by glutaminase inhibition ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}).

The dependency on glutamine-derived glutamate that we observe in cells with NRF2 activation is primarily due to defective TCA cycle anaplerosis and not the limited availability of glutamate for antioxidant production, since neither antioxidant supplementation ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}, and [Figure 4A](#fig4){ref-type="fig"}) nor pharmacological decrease of GSH levels ([Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}) rescued glutamine dependency or CB-839 sensitivity. The ability of both pyruvate and DMG to rescue overall levels in TCA cycle metabolites as well as cellular proliferation and reduced mitochondrial respiration in response to CB-839 treatment highlights that glutaminase inhibition further depletes limited intracellular glutamate stores in *KEAP1* mutant cells and exacerbates basal defects in the TCA cycle. Reduced TCA cycle output in *KEAP1* mutant cells can have wide ranging effects beyond immediate use in biosynthesis pathways, it may also impact the activity of αKG-dependent deoxygenases, a family of enzymes that regulate signaling, metabolism, and epigenetic modifications ([@bib48]). αKG, succinate, and fumarate levels can have wide ranging effects beyond immediate use in biosynthesis pathways by altering hypoxia-inducible transcription factor (HIF) signaling ([@bib61]; [@bib36]; [@bib3]) and altering gene expression through epigenetic modifications ([@bib80]; [@bib45]; [@bib75]).

We show that the decrease in intracellular glutamate availability for the TCA cycle, in the context of increased NRF2, occurs through the active secretion of glutamate through xCT/SLC7A11. We hypothesize that xCT/SLC7A11-mediated secretion of glutamate and import of cystine is driven by the increased intracellular demand for cysteine, a key amino acid for many NRF2-induced antioxidants (e.g. GSH, TXN). Alternatively, the levels of glutamate and cystine in culture medium in vitro or in serum in vivo can also modulate the directionality of xCT/SLC7A11 ([@bib4]), which may also change the availability of intracellular glutamate for central carbon metabolism and the dependency on exogenous glutamine (Muir, A. *et al*, co-submitted with this manuscript). Similar to our findings, depletion of xCT/SLC7A11 improves cancer cell viability after glucose withdrawal through conservation of intracellular glutamate levels to maintain mitochondrial respiration ([@bib40]; [@bib64]). In this context, *SLC7A11* expression was also dependent on the transcription factor ATF4, which is known to cross talk with NRF2 in cancer cell metabolism ([@bib17]).

NRF2 is a pleiotropic transcription factor that regulates many genes and pathways that could contribute to the depletion of intracellular glutamate stores in *Keap1* mutants and facilitate metabolic rewiring ([@bib68]). In line with this, using pharmacological and genetic means to modulate GSH levels specifically was not sufficient to alter sensitivity to CB-839 ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"} and [Figure 4D](#fig4){ref-type="fig"}). Interestingly, increased endogenous expression of *Slc7a11* in combination with *Gclc* or *Gclm* using SAM CRISPRa ([@bib60]), was sufficient to induce sensitivity to CB-839 in KP SAM CRISPRa cells ([Figure 4D](#fig4){ref-type="fig"}). However, the sensitivity to CB-839 was not as robust as in KPK cells, suggesting that the moderate increase in target genes and GSH synthesis in double sg KP SAM CRISPRa cells was not enough to fully recapitulate the metabolic phenotype of *Keap1* mutant cells.

Tumor progression occurs in a complex microenvironment with infiltrating immune cells and fibroblasts, which can impact tumor growth ([@bib66]). In addition to its cell-autonomous effects, glutamate secretion can signal to cells in the microenvironment through non cell-autonomous mechanisms ([@bib4]). Increased glutamate secretion and paracrine signaling from tumors with NRF2 activation may have a profound impact on both the function and the cellular composition of cells in the microenvironment ([@bib57]). Altered levels of both glutamine and glutamate in the tumor microenvironment of *KEAP1* mutant tumors can effect cell signaling and regulate cell growth and proliferation pathways ([@bib56]; [@bib43]; [@bib52]).

Glutamine metabolism is positively regulated by a variety of oncogenes, rendering many cancer types addicted to glutamine and making glutamine metabolism an attractive therapeutic target ([@bib77]). Hence, there are several small molecule glutaminase inhibitors, one of which, CB-839, is currently in phase I clinical trials ([@bib1]). However, our data as well as previous studies highlight the potential importance of stratifying patients based on genotype for a successful response to glutaminase inhibitors. In a previous study, we have reported that *KEAP1* mutant tumors respond to CB-839 treatment, while growth of wild type tumors is unaffected in vivo ([@bib57]). Taken together with the current study, which provides mechanistic insight into how *KEAP1* mutations rewire tumor metabolism and why glutamine deprivation results in growth suppression, these data provide critical pre-clinical evidence supporting the treatment of patients with *KEAP1* mutations with glutaminase inhibitors. We further provide evidence that mutations in *KEAP1* are sufficient to predict sensitivity to glutaminase inhibitors regardless of tissue of origin. CB-839 treatment significantly suppressed cell growth in a panel of tumor cells including melanoma, bone, colon, renal, squamous, and urinary tract cancers with *KEAP1* mutations. Additionally, use of KI696, a small molecule activator of NRF2, which blocks the interaction between NRF2 and KEAP1, was able to sensitize both mouse and human *KEAP1* WT cell lines to glutaminase inhibition. These data argue that the use of glutaminase inhibitors along with small molecule activators of NRF2 could be an effective therapeutic strategy with broad application across various *KEAP1* mutant and wild-type cancers.

Materials and methods {#s4}
=====================

Cell lines and culture {#s4-1}
----------------------

KP and KPK isogenic clonal cell lines were previously established ([@bib57]). Human cell lines were acquired from ATCC. All lines were tested negative for mycoplasma. All cells were cultured in a humidified incubator at 37°C and 5% CO~2~. Cells were maintained in either DMEM or RPMI-1640 (Cellgro, Corning; Manassas, Virginia) supplemented with 10% fetal bovine serum (Sigma Aldrich, St. Louis, Missouri) and gentamicin (Invitrogen, ThermoFisher; Waltham, Massachusetts).

Cell proliferation and viability assays {#s4-2}
---------------------------------------

For cell proliferation assays conducted under different drug or media conditions as indicated, cells growing in DMEM were trypsinized, counted and plated into 12 well plate dishes (BD/Falcon, Corning; Manassas, Virginia) in 1 mL of RPMI media. For glutamine deprivation experiments, cells were seeded in RPMI containing either 2 mM or 0.5 mM glutamine at the time of plating. After cell attachment, cells were treated with the indicated drugs: vehicle (DMSO), 500 nM erastin (Sigma Aldrich) 6 mM glutamate (Sigma Aldrich), 50 uM Trolox (Acros Organics, Fisher Scientific; Waltham, Massachusetts), 0.5 mM *N*-acetyl-L-cysteine (NAC, Sigma Aldrich), 2 mM pyruvate (Gibco, ThermoFisher Scientific; Waltham, Massachusetts), 2 mM dimethyl-2-oxoglutarate (DMG, Sigma Aldrich), L-Buthionine sulfoximine (Sigma Aldrich), hydrogen peroxide (LabChem, Zelienople, Pennsylvania), menadione (Sigma Aldrich) or 1 μM KI696 (provided by Craig Thomas). Cells exposed to galactose oxidase (Sigma Aldrich) were cultured in media supplemented with 5 mM galactose (Sigma Aldrich). After 12 hr, cells were treated with 250 nM CB839. For media in which cystine concentrations were lowered to 20 μM, RPMI was prepared from a powder mix without amino acids (US Biological, Salem, Massachusetts) according to manufacturers instructions. All amino acids besides cystine were added to the RPMI mixture in the same concentrations as present in RPMI-1640 formulation. Proliferation experiments were carried out for 5 days post drug treatment and collected either by staining or cell counting. Cell counts were collected by trypan blue exclusion on a Countess II automated cell counter (Life Technologies, ThermoFisher Scientific; Waltham, Massachusetts). Cells were stained with a 0.5% crystal violet solution in 25% methanol. Plates were then washed, dried, and crystal violet was eluted in 400 uL of 10% acetic acid.

For cell viability assays cells were plated in a white, opaque 96-well plate with clear bottom at a density of 1000 cells/well in RPMI. Drugs were added at the same concentration and manner as described above for the indicated amount of time. After 4 days, cell viability in the presence of all compounds was assessed by cell titer glo (Promega \#G7570, Madison, Wisconsin).

qPCR analysis {#s4-3}
-------------

mRNA was collected from cells with RNeasymini kit (Qiagen, Germany) according to manufacturers protocol. Complementary DNA (cDNA) was synthesized from extracted mRNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems \#4368814, ThermoFisher Scientific; Waltham, Massachusetts) according to manufacturers protocol. Gene expression was analyzed by quantitative reverse transcription polymerase chain reaction on a CFX96 Real-Time System (BioRad Technologies, Hercules, California) with the following primers, *Slc7a11*: gattcatgtccacaagcacac and gagcatcaccatcgtcagag*, SLC7A11*: ccatgaacggtggtgtgtt, *Gclc*: agatgatagaacacgggaggag and tgatcctaaagcgattgttcttc, *GCLC*: atgccatgggatttggaat and gatcataaaggtatctggcctca, *Nqo1*: acgctgccatgtatgacaaa and ggatcccttgcagagagtaca, *NQO1*: acgctgccatgtatgacaaa and ggatcccttgcagagagtaca, *Gclm:* tgactcacaatgacccgaaa and tcaatgtcagggatgctttct.

Immunoblotting {#s4-4}
--------------

Cells were lysed in 150 uL of ice-cold RIPA buffer supplemented with 1X Complete Mini inhibitor mixture (Roche, \#11 836 153 001, Switzerland) and mixed on a rotator at 4°C. Protein concentration of lysates was determined using the Bio-Rad DC Protein Assay (\#500--0114). 20--40 ug of total protein was separated on a 4--12% Bis-Tris gradient gel (Bio-Rad) by SDS-PAGE and then transferred to nitrocellulose membrane (Bio-Rad). The following antibodies were used for immunoblotting: anti-Nrf2 (Cell Signaling Technologies, Danvers, Massachusetts, \#12721, 1:1000), anti-HSP90 (BD, Sparks, Maryland, \#610418, 1:4000), anti-H3 (AbCam, Cambridge, Massachusetts, \#1991, 1:4000), and anti-Slc7a11 (Novus Biologicals, Littleton, Colorado, \#NB300-318).

Glutathione assay {#s4-5}
-----------------

Total glutathione was measured after treatment with 250 nM CB-839 or treatment with BSO for 24 hr where indicated and collected according to manufacturer's protocol (Promega, V6611). Data was normalized to additional wells that received identical conditions using Cell Titer Glo (Promega, G7570).

ROS analysis {#s4-6}
------------

ROS in cultured cells were measured by incubating cells with 5 μM CM-H2DCFDA (C6827, Life Technologies) for 30 min at 37°C. DCF fluorescence was acquired on the Attune NxT (ThermoFisher) flow cytometer and analyzed using FlowJo software (Tree Star, Ashland, Oregon).

Mitochondrial respiration {#s4-7}
-------------------------

Oxygen consumption rate (OCR) experiments were performed using the XFe-96 apparatus from Seahorse Bioscience (Agilent, Santa Clara, California). Cells were seeded to \~80% confluence in at least triplicate for each condition in RPMI. The following day, wells were treated with 250 nM CB-839 for 4 hr. Media was completely replaced with reconstituted RPMI with 12.5 mM glucose and 2 mM glutamine (no sodium bicarbonate) adjusted to pH 7.4 and incubated for 45 min at 37°C in a CO~2~-free incubator prior to measurements. Maximal respiration measurements were obtained by performing a mito-stress test. Briefly, cells were prepared as described above. After reaching steady-state respiratory flux (basal respiration), 100 μM oligomycin was injected to inhibit ATP synthase. Next, respiration was uncoupled from oxidative phosphorylation by addition of carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (Sigma)until maximal respiratory capacity was reached (up to 2 μM in 0.5 μM increments). Finally, respiration was inhibited by the addition of 50 μM rotenone and 50 μM antimycin A (Sigma).

Animal experiments {#s4-8}
------------------

All animal studies described were approved by the NYU Langone Medical Center Institutional Animal Care and Use Committee. 1 × 10^6^ cells were implanted subcutaneously into NSG mice. After tumor establishment phase (13 days post implantation), animals were randomized and assigned to the following groups: vehicle treated and doxycycline diet, vehicle treated and normal diet, CB-839 treated and doxycycline diet, or CB-839 treated and normal diet. Animals were treated with 200 mg/kg CB-839 or vehicle (Calithera, San Francisco, California) twice daily administered through oral gavage as before ([@bib11]). The vehicle contained 25% (w/v) hydroxypropyl-β-cyclodextrin in 10 mmol/L citrate (pH 2.0), and CB839 was formulated at 20 mg/mL for a final dosing volume of 10 mL/kg.

Glutamate secretion {#s4-9}
-------------------

Extracellular glutamate was measured by collecting fresh and spent medium after 24 hr of growth. Cells were assumed to grow exponentially over the culture period. Media was analyzed using a YSI biochemistry analyzer (Yellow Springs Instruments, Yellow Springs, Ohio).

shRNA and sgRNA cloning and cell line generation {#s4-10}
------------------------------------------------

Doxycyline-induced knockdown of xCT was achieved by cloning miR-E shRNAs targeting *Slc7a11* into the LT3GEPIR vector as previously described in detail ([@bib20]). Briefly, LT3GEPIR was digested with XhoI and EcoRI, and purified with a gel extraction kit (Qiagen). Single stranded ultramers were amplified with forward primer miRE-XhoI (5'‐ TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG‐3') and reverse primer miRE‐EcoRI (5'‐TCTCGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGC‐3'). Amplicons were gel purified, digested with XhoI and EcoRI, cleaned up with PCR purification kit (Qiagen) and ligated into the cut LT3GEPIR vector with T4 DNA Ligase at a 3:1 insert:vector molar ratio. Vectors were transduced into cells and selected with 3 and 6 ug/ml puromycin for three plus three days. Knockdown of xCT/*Slc7a11* was verified by western blot and qPCR analysis following 72 hr of treatment with 1 ug/ml doxycycline. Cell lines transduced with the first two efficient shRNAs (\#1 and \#3), along with a non-efficient shRNA as control (\#5), were used in the study. Sequences of ultramers obtained from Integrated DNA Technologies (Coralville, Iowa):

\#1 -

TGCTGTTGACAGTGAGCGCCAGGAAGAGACACAAGTCTAATAGTGAAGCCACAGATGTATTAGACTTGTGTCTCTTCCTGATGCCTACTGCCTCGGA

\#2 -

TGCTGTTGACAGTGAGCGCAAGGAAGATTTTAGTTATTAATAGTGAAGCCACAGATGTATTAATAACTAAAATCTTCCTTTTGCCTACTGCCTCGGA

\#3 --

TGCTGTTGACAGTGAGCGCCAGGAGCTTTATGTAAATGTATAGTGAAGCCACAGATGTATACATTTACATAAAGCTCCTGATGCCTACTGCCTCGGA

\#5 --

TGCTGTTGACAGTGAGCGCCAGATTATACTAGAAGTTGTATAGTGAAGCCACAGATGTATACAACTTCTAGTATAATCTGTTGCCTACTGCCTCGGA

\#6 --

TGCTGTTGACAGTGAGCGCTAAGTTCTATGTGATACAGAATAGTGAAGCCACAGATGTATTCTGTATCACATAGAACTTATTGCCTACTGCCTCGGA

\#7 --

TGCTGTTGACAGTGAGCGCAGGAACTATGTTTGTACTAAATAGTGAAGCCACAGATGTATTTAGTACAAACATAGTTCCTATGCCTACTGCCTCGGA

\#8 -

TGCTGTTGACAGTGAGCGCCCAGAAGACTCTAAAGAATTATAGTGAAGCCACAGATGTATAATTCTTTAGAGTCTTCTGGTTGCCTACTGCCTCGGA

Transcriptional activation of various genes was achieved by cloning sgRNAs targeting the region upstream of the transcriptional start sites for *Slc7a11*, *Gclc*, and *Gclm* into the lenti sgRNA(MS2)\_puro and zeo backbones (Addgene plasmid \#73797 and 61247, respectively) as previously described ([@bib9]). Briefly, both backbones were digested with Bsmb1 (New England Biosciences, Ipswich, Massachusetts) and purified with a gel extraction kit (Qiagen). Single stranded oligo's were annealed and phosphorylated using T4 PNK (New England Biosciences). Phosphorylated and annealed oligos were then ligated into the purified digested backbones using Quick Ligase (New England Biosciences). Vectors were transduced into KP cells already containing the other two component vectors for the SAM system and selected with 3 and 6 ug/ml puromycin for three plus three days. Transcriptional activation was subsequently verified by qPCR. Sequences of oligos obtained from Integrated DNA Technologies:

sg*Slc7a11*:

sense- CACCGCCTGTCACACCAACTTACT

antisense- AAACAGTAAGTTGGTGTGACAGGC

sg*Gclc:*

sense- CACCGAATAAGGACTGAAAAGTCT

antisense- AAACAGACTTTTCAGTCCTTATTC

sg*Gclm*:

sense: CACCGGTGACTGGCCCTCGGCCTG

antisense: AAACCAGGCCGAGGGCCAGTCACC

GC/MS analysis of polar metabolites and stable isotope tracing {#s4-11}
--------------------------------------------------------------

For glutamine tracing, 2 × 10^5^ cells were seeded in 2 mL of RPMI-1640 in 6 well plates. Where indicated, cells were pretreated for 12 hr with 1 μM of KI696. Media was then replaced with 2 mL of fresh RPMI-1640 containing 2 mM of \[U-^13^C\]-L-glutamine (Cambridge Isotope Laboratory, Tewksbury, Massachusetts) and 1 μM of KI696 where indicated. For PC flux analysis, 1 × 10^5^ cells were seeded in 1 mL of RPMI Cells were cultured for 8 hr to reach steady state labeling of TCA cycle intermediates. Cells were washed 1X in ice cold saline and then collected by scraping in 600 uL of 80% (v/v) of ice cold methanol containing 1.4 ug/mL norvaline (Sigma Aldrich). Samples were vortexed for 10 min at 4°C and then centrifuged at max speed for 10 min. Supernatant was transferred to fresh tubes and then dried under nitrogen. Dried and frozen metabolite extracts were then derivatized with 16 uL of MOX reagent (ThermoFisher) for 60 min at 37°C and *N*-tert-butyldimethylchlorosilane (Sigma Aldrich) for 30 min at 60°C. After derivatization, samples were analyzed by GC-MS using a DB-35MS column (Agilent Technologies) in an Agilent 7890A gas chromatograph coupled to an Agilent 5997B mass spectrometer. Helium was used as the carrier gas at a flow rate of 1.2 mL/minute. One microliter of sample was injected in split mode (split 1:1) at 270°C. After injection, the GC oven was held at 100°C for 1 min and then increased to 300°C at 3.5 °C/minute. The oven was then ramped to 320°C at 20 °C/minute and held for 5 min at 320°C.

The MS system operated under electron impact ionization at 70 eV and the MS source and quaddrupole were held at 230°C and 150°C respectively. The detector was used in scanning mode, and the scanned ion range was 10--650 m/z. Mass isotopomer distributions were determined by integrating appropriate ion fragments for each metabolite ([@bib47]) using MatLab (Mathworks, Natick, Massachusetts) and an algorithm adapted from Ferandez and colleagues ([@bib21]) that corrects for natural abundance.

Statistics {#s4-12}
----------

Values are presented as mean ± SEM. For statistical analyses, we used Graphpad Prism software v.7.02 (La Jolla, California): one-way ANOVA with Tukey's post-hoc test for cell growth assays, OCR measurements, Glutathione levels and TCA Metabolites in [Figure 4e](#fig4){ref-type="fig"}; Mann-Whitney test for intra and extra cellular Glutamate levels and \[U-^13^C\]-L glutamine labeled metabolites in [Figure 3e](#fig3){ref-type="fig"}; 2-sided Student's t-test for gene expression analyses and TCA Metabolites in [Figure 3c](#fig3){ref-type="fig"}; and two-way ANOVA for tumor growth. All experiments were repeated at least twice unless otherwise stated. All *n* indicate biological replicates.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Activation of the NRF2 antioxidant program causes defects in central carbon metabolism\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Sean Morrison as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Oliver DK Maddocks (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

These authors studied metabolic reprogramming downstream of activating the Nrf2 transcriptional program in cancer cells. Nrf2 is negatively regulated by Keap1, and gain of function mutations in this pathway occur in lung cancer. The authors find that mutating Keap1 sensitizes cultured cells to glutamine deprivation and to glutaminase inhibitors. The mechanism involves enhanced glutamate export via SLC7A11, which allows cells to import cystine to meet demands for glutathione biosynthesis. Inhibiting SLC7A11 reverses sensitivity to glutaminase inhibition in culture and in tumors. The authors go on to provide evidence that Nrf2 activation imposes an addiction to anaplerosis from glutamine, such that TCA cycle metabolism declines when glutaminase is inhibited; these cells can be rescued by providing alternative anaplerotic precursors. Importantly, pharmacological activation of the Nrf2 pathway is sufficient to addict cells to glutamine. Thus, the authors propose a balance between glutamine anaplerosis and cysteine-based antioxidant production that could provide a therapeutic window for glutaminase inhibitors.

Overall, the reviewers found the paper to be solid, clearly presented, and focused on an interesting topic. With glutaminase inhibitors in clinical trials but lacking enrollment biomarkers, the main findings of the paper could have translational relevance. However, the reviewers also identified a few areas where the paper could be improved.

Essential revisions:

1\) In the context of this paper there are three main ways that glutamate is utilized: (1) TCA cycle, (2) cystine/glutamate exchange, and (3) GSH synthesis. The sensitivity of KPK cells to glutaminase inhibition is rescued by providing TCA cycle precursors (pyruvate, DMG), or by blocking cystine/glutamate exchange, whereas anti-oxidants (trolox & NAC) fail to rescue CB839 sensitivity. This is taken as evidence that GSH synthesis is the least important of the three glutamate sinks. However, a better way to test this is to diminish GSH synthesis directly (e.g. use intermediate doses of BSO in KPK cells to decrease GSH synthesis to KP cell levels).

2\) It would be useful to test if adding TCA cycle precursors (pyruvate/DMG) to KPK cells under basal conditions (i.e. without any inhibitors present) increases TCA cycle metabolite levels and oxygen consumption. This would confirm that glutamate availability is genuinely a metabolic \"bottleneck\" for TCA cycle/OXPHOS in these cells.

3\) Nrf2 activation itself does not impede proliferation under normal conditions despite diminishing anaplerosis/TCA cycle/OXPHOS. If this is the case then an overall interpretation of the paper could be that the KPK cells sacrifice excess TCA cycle capacity for excess anti-oxidant capacity, which might be an appealing trade-off during tumorigenesis. This is worth clarifying because it would help explain selection for Nrf2-activating mutations, and would help differentiate this paper from previous work (e.g. PMID: 28429737, 22789539). Do KPK cells have lower ROS levels than KP cells under basal conditions? Are KPC cells more resistant to elevated ROS levels (e.g. H~2~O~2~) than KP?

4\) Why does pyruvate rescue cells subjected to CB-839 or glutamine deprivation? Pyruvate is ostensibly not limiting under these conditions, and adding more of it does not rescue OCR. The implication is that pyruvate provides an alternative anaplerotic substrate via pyruvate carboxylase, but this should be validated.

5\) p53 is known to inhibit cystine transporter activity (Jiang L et al., Nature 520, 57-62). Does adding cisplatin to activate p53 in both KP and KPK cells alter sensitivity to glutaminase inhibition? If so, this would broaden the impact of the findings.

10.7554/eLife.28083.018

Author response

> Essential revisions:
>
> 1\) In the context of this paper there are three main ways that glutamate is utilized: (1) TCA cycle, (2) cystine/glutamate exchange, and (3) GSH synthesis. The sensitivity of KPK cells to glutaminase inhibition is rescued by providing TCA cycle precursors (pyruvate, DMG), or by blocking cystine/glutamate exchange, whereas anti-oxidants (trolox & NAC) fail to rescue CB839 sensitivity. This is taken as evidence that GSH synthesis is the least important of the three glutamate sinks. However, a better way to test this is to diminish GSH synthesis directly (e.g. use intermediate doses of BSO in KPK cells to decrease GSH synthesis to KP cell levels).

To address this point we cultured KPK cells in decreasing doses of BSO, which decreased GSH synthesis and total GSH levels in a dose dependent manner ([Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}). When KPK cells are treated with CB-839 in the presence of BSO, at concentrations that reduce the total GSH levels to KP cell levels or lower, we observe no change in sensitivity to glutaminase inhibition ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). These experiments directly address essential comment 1, suggesting that GSH synthesis is the least important glutamate sink.

To further address essential Comment 1, we took a genetic approach. We used the CRISPR synergistic activation mediator system (SAM CRISPRa) ([Figure 4C](#fig4){ref-type="fig"}), which takes advantage of the DNA targeting capabilities of a catalytically dead Cas9 protein fused to VP64 and a modified sgRNA that recruits and targets transcriptional activators to promoter regions upstream of transcriptional start sites of genes of interest to enhance endogenous transcription. Utilizing SAM CRISPRa, we increased expression of *Gclc* and *Gclm*, enzymes involved in the rate-limiting step of GSH synthesis, as well as *Slc7a11* either alone or in combination with *Gclc* or *Gclm* in KP cells. In all cases we were able to increase expression of the targeted gene ([Figure 4C](#fig4){ref-type="fig"}). Additionally, increased gene expression of individual targets or in combination increased total GSH levels ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). However, increased GSH production per se in these cell lines did not result in increased sensitivity to CB-839 treatment. We did observe an increase in CB-839 sensitivity in KP SAM CRISPRa cells with double guides (sg*Slc7a11* and sg*Gclm*/sg*Gclc*) ([Figure 4D](#fig4){ref-type="fig"}), however, the sensitivity was not equivalent to what we observed in KPK cells.

These results further emphasize that GSH synthesis is the least important glutamate sink and also highlight that altering GSH levels alone is not sufficient to recapitulate CB-839 sensitivity.

While SAM CRISPRa induces transcription of genes from endogenous loci, levels of gene induction and GSH levels could not be induced to levels equivalent to KPK cells (3-10 fold vs 10-100 fold gene expression and 1.5-2 fold vs 3 fold GSH levels in KP SAM CRISPRa and KPK cells respectively). This difference in induction of gene expression could explain the limited increase in sensitivity to CB-839 seen in KP SAM CRISPRa cells compared to KPK cells. However, Nrf2 is a pleiotropic transcription factor that is known to regulate a plethora of antioxidant genes. Therefore, we cannot exclude the possibility that induction of additional genes (including other antioxidants such as Thioredoxin) resulting from constitutive active Nrf2 signaling are required to fully recapitulate the metabolic rewiring resulting in robust sensitivity to CB-839 in KPK cells.

We have added a paragraph in the Discussion section to discuss and address these points.

> 2\) It would be useful to test if adding TCA cycle precursors (pyruvate/DMG) to KPK cells under basal conditions (i.e. without any inhibitors present) increases TCA cycle metabolite levels and oxygen consumption. This would confirm that glutamate availability is genuinely a metabolic \"bottleneck\" for TCA cycle/OXPHOS in these cells.

Please see supplemental [Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"} and B to address this point. We have measured the levels of TCA cycle intermediates in KP and KPK cells after treatment with 2mM pyruvate or 2mM DMG. We see that addition of either metabolite increases the relative abundance of TCA cycle intermediates in KPK cells. The increase in TCA cycle metabolites we observe in KPK cells is either equivalent to or in excess of the levels of these intermediates in KP cells in normal media conditions ([Figure 3C](#fig3){ref-type="fig"}). Additionally, both pyruvate and DMG supplementation elevate basal levels of OCR in the presence of CB-839 ([Figure 3G](#fig3){ref-type="fig"}). However, in normal media conditions, without the addition of CB-839, the supplementation of either pyruvate or DMG does not result in a significant increase in OCR in KPK cells ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). We believe that is a result of reduced reserve respiratory capacity in KPK cells as compared to KP cells ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). Basal OCR is \~75% of maximal OCR in KPK cells. It is likely more difficult to increase basal respiration in these cells since mitochondria are functioning at close to maximal capacity whereas in KP cells, there is a greater reserve respirator capacity ([Figure 3](#fig3){ref-type="fig"}---figue supplement B) and we do see that supplementation with either pyruvate or DMG significantly increases OCR ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}).

> 3\) Nrf2 activation itself does not impede proliferation under normal conditions despite diminishing anaplerosis/TCA cycle/OXPHOS. If this is the case then an overall interpretation of the paper could be that the KPK cells sacrifice excess TCA cycle capacity for excess anti-oxidant capacity, which might be an appealing trade-off during tumorigenesis. This is worth clarifying because it would help explain selection for Nrf2-activating mutations, and would help differentiate this paper from previous work (e.g. PMID: 28429737, 22789539). Do KPK cells have lower ROS levels than KP cells under basal conditions? Are KPC cells more resistant to elevated ROS levels (e.g. H~2~O~2~) than KP?

We have clarified this point clearly in the Discussion. In addition, we assessed ROS levels and sensitivity to ROS inducing agents like the reviewers suggested. Basally, KPK cells have much lower ROS levels compared to KP cells ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) and are indeed more resistant to oxidative stress, exemplified with treatment with H~2~O~2~ ([Figure 1B](#fig1){ref-type="fig"}) as well as other oxidizing agents such as galactose oxidase ([Figure 1C](#fig1){ref-type="fig"}) and menadione ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}).

> 4\) Why does pyruvate rescue cells subjected to CB-839 or glutamine deprivation? Pyruvate is ostensibly not limiting under these conditions, and adding more of it does not rescue OCR. The implication is that pyruvate provides an alternative anaplerotic substrate via pyruvate carboxylase, but this should be validated.

Pyruvate supplementation does modestly, but significantly increase OCR in the presence of CB-839 ([Figure 3G](#fig3){ref-type="fig"}). However, it is likely that there is increased carbon flux through pyruvate carboxylase in efforts to continue to fuel the TCA cycle when glutamate availability is limited by treatment with CB-839. To address this issue, we performed tracing experiments using stable-isotope labeled glucose (3C^13^-D-Glucose) to look at PC flux in normal media conditions as well as labeled pyruvate (1C^13^-Pyruvate) to look at PC flux in the context of pyruvate rescue. We observe that treatment with CB-839 increases PC flux in normal media as well as when media is supplemented with pyruvate ([Figure 3I and J](#fig3){ref-type="fig"}). This suggests that when glutamate availability is limited cells divert more glucose-derived carbon through PC to help replenish the TCA cycle.

> 5\) p53 is known to inhibit cystine transporter activity (Jiang L et al., Nature 520, 57-62). Does adding cisplatin to activate p53 in both KP and KPK cells alter sensitivity to glutaminase inhibition? If so, this would broaden the impact of the findings.

Inactivation of p53 occurs in a large percentage of human tumors. The mouse model from which our KP and KPK cell lines are derived from models lung cancer through the constitutive activation of Kras by expression of the endogenous Kras^G12D^ allele and concomitant loss of p53. Additionally, the human LUAD cell lines as well as cell lines from other cancer subtypes used throughout this paper are also p53 mutants preventing us from utilizing strategies to activate p53 in the cell lines in this manuscript. Despite this, we tested the differential sensitivity to cisplatin between KP and KPK cells and saw no difference. In addition there was no difference in CB-839 sensitivity in combination with cisplatin in both KP and KPK cells (data not shown). As the initial question raised by reviewers was not possible to be addressed in our system, we felt the data not relevant to include in the revised version of the manuscript.

[^1]: ^\#^These authors contributed equally to this work.

[^2]: These authors contributed equally to this work.
